Application of galangal polysaccharide in preparing a preparation for improving intestinal flora dysregulation

Abstract

The present invention belongs to the technical field of biomedicine and relates to the application of galangal polysaccharide in the preparation of a preparation for improving intestinal flora imbalance. The galangal polysaccharide provided by the present invention can effectively improve intestinal flora imbalance, especially improve the intestinal flora imbalance induced by hyperuricemia. Hyperuricemia can cause intestinal barrier damage, which in turn leads to intestinal flora translocation and induces flora imbalance. Galangal polysaccharide can up-regulate Occludin and ZO-1, repair intestinal barrier damage, and improve intestinal integrity. After the action of galangal polysaccharide, it has a greater impact on the intra-group diversity Beta diversity of the flora, can reverse the deviation of the flora structure caused by hyperuricemia, and relieve the deviation of the intestinal flora structure. The galangal polysaccharide provided by the present invention is a potential new prebiotic, which has excellent effects in improving intestinal flora imbalance and has good application prospects.

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine and relates to an application of galangal polysaccharide in preparing an agent for improving intestinal flora imbalance. Background Art

[0002] Alpinia officinalis is the rhizome of the ginger plant Alpinia officinalis. It is pungent and hot in nature and belongs to the spleen and stomach meridians. It has the functions of warming the stomach and stopping vomiting, dispelling cold and relieving pain. It is often used for cold pain in the abdomen, vomiting due to stomach cold, belching, acid regurgitation and other symptoms. At present, the research on Alpinia officinalis at home and abroad mainly focuses on chemical components such as flavonoids and aromatic oils and pharmacological functions such as antibacterial, anti-tumor, and hypolipidemic. There are still few studies on Alpinia officinalis polysaccharides. Prior art Chinese patents CN108997510A and CN118027233A respectively disclose the antioxidant application of Alpinia officinalis polysaccharides and their application in improving insulin resistance, showing that Alpinia officinalis polysaccharides have good development and application prospects, and their functional activity needs to be further explored.

[0003] Intestinal dysbiosis refers to a state in which the intestinal flora changes from a physiological combination to a pathological combination, which is manifested by changes in flora diversity, richness and flora composition structure. The degree of dysbiosis varies. Mild imbalance does not cause changes in the body. Moderate imbalance may develop into serious gastrointestinal diseases. Severe dysbiosis can affect various organs and disrupt the balance of the whole body. There are many factors that induce intestinal dysbiosis, and the degree and phenotype of dysbiosis caused by different factors are often different. Studies have found that the occurrence and development of hyperuricemia are closely related to intestinal dysbiosis. Hyperuricemia can damage the intestinal barrier and cause intestinal dysbiosis. At present, improving intestinal dysbiosis and improving hyperuricemia through prebiotics is an effective way.

[0004] Plant polysaccharides are macromolecules, and their oral utilization is low due to molecular weight limitations. In recent years, as research progresses, it has gradually been shown that carbohydrate-active enzymes in the intestinal flora can utilize and decompose them to produce favorable metabolites and achieve the purpose of adjusting the flora structure. Therefore, it is considered to be a potential prebiotic substance. In order to further study the biological activity of galangal polysaccharides, seek regulatory measures to alleviate hyperuricemia-induced intestinal flora imbalance, and explore the application of galangal polysaccharides in improving intestinal flora imbalance, it is of great significance. Summary of the invention

[0005] In order to solve the above technical problems, the present invention separates and extracts galangal polysaccharides from galangal, and uses molecular biology methods and animal models to further study the regulatory effect of galangal polysaccharides on intestinal dysbacteriosis, aiming to provide a new prebiotic substance for improving intestinal dysbacteriosis, provide an application of galangal polysaccharides in the preparation of a modulator for improving intestinal dysbacteriosis, and promote the high-value utilization of galangal polysaccharides.

[0006] On the one hand, the present invention provides an application of galangal polysaccharide in the preparation of a preparation for improving intestinal flora imbalance, and the galangal polysaccharide is obtained by extracting from galangal.

[0007] Further, in the above application, the intestinal flora imbalance is high uric acid-induced intestinal flora imbalance; the intestinal flora imbalance includes intestinal barrier damage and / or deviation of the flora structure.

[0008] Further, in the above application, the intestinal barrier damage includes down-regulation of the expression of tight junction protein Occludin and / or ZO-1 protein representing intestinal barrier integrity; the deviation of the flora structure includes significant changes in Beta diversity representing the intra-group and inter-group diversity of the intestinal flora.

[0009] Further, in the above application, the administration method of the galangal polysaccharide is intragastric administration.

[0010] Further, in the above application, the galangal polysaccharide repairs the intestinal barrier damage induced by high uric acid, and the administration concentration of the galangal polysaccharide is 75 mg / kg to 250 mg / kg.

[0011] Further, in the above application, the administration concentration of the galangal polysaccharide is 250 mg / kg.

[0012] Further, in the above application, the galangal polysaccharide alleviates the deviation of the flora structure induced by high uric acid, and the alleviation is achieved by regulating the Beta diversity of the intestinal flora.

[0013] Further, in the above application, the regulation of the Beta diversity of the intestinal flora includes down-regulating Firmicutes and / or down-regulating Planctomycetes and / or down-regulating Proteobacteria and / or up-regulating Bacteroidetes at the phylum level of the intestinal flora composition.

[0014] Further, in the above application, the regulation of the Beta diversity of the intestinal flora includes down-regulating the genus Lachnospiraceae_NK4A136_ and / or down-regulating the genus Clostridium and / or up-regulating the genus Ruminococcus and / or up-regulating the genus Eubacterium at the genus level of the intestinal flora composition.

[0015] Further, in the above application, the preparation of the galangal polysaccharide includes extracting crude galangal polysaccharide from galangal, then performing enzymatic hydrolysis with papain to remove proteins, and adsorbing and removing small molecule peptides and pigments with XAD-16 macroporous resin to obtain galangal polysaccharide.

[0016] Compared with the prior art, the technical solution provided by the present invention has at least the following beneficial effects or advantages:

[0017] (1) The present invention provides a preparation method of galangal polysaccharide through process optimization, and the galangal polysaccharide prepared by this method has higher purity.

[0018] (2)The galangal polysaccharide provided by the present invention has excellent improvement effect on intestinal flora imbalance induced by hyperuricemia in regulating intestinal flora imbalance.

[0019] (3)The galangal polysaccharide provided by the present invention regulates the Beta diversity of intestinal flora by down-regulating the genus Lachnospiraceae_NK4A136_, down-regulating the genus Clostridium, up-regulating the genus Ruminococcus, and up-regulating the genus Eubacterium at the genus level of intestinal flora composition, and alleviates the deviation of flora structure induced by hyperuricemia.

[0020] The galangal polysaccharide provided by the present invention is a novel prebiotic substance for improving intestinal flora imbalance, and can be applied to the preparation of preparations for improving intestinal flora imbalance, so as to promote the high-value utilization of galangal polysaccharide. Description of the Drawings

[0021] Figure 1 It is the determination result of the relative expression levels of tight junction proteins Occludin and ZO-1 in the colon tissue proteins of mice in different experimental groups. Among them, A is the immunoblot protein band diagram of tight junction proteins Occludin and ZO-1 in the colon tissue proteins of mice in different experimental groups; B is the statistical result diagram of the relative expression levels of tight junction proteins Occludin and ZO-1 in the colon tissue proteins of mice in different experimental groups; * indicates significant difference compared with the control group (p<0.05), and # indicates significant difference compared with the model group (p<0.05).

[0022] Figure 2 It is the determination result of the Beta diversity of mice in different experimental groups.

[0023] Figure 3 It is the determination result of the main phylum-level composition of intestinal flora of mice in different experimental groups. Among them, A is the clustering abundance diagram of the phylum level of intestinal flora of mice in different experimental groups; B is the relative abundance expression of Firmicutes in different experimental groups; C is the relative abundance expression of Bacteroidetes in different experimental groups; D is the ratio of the relative abundance expressions of Firmicutes and Bacteroidetes in different experimental groups; E is the relative abundance expression of Planctomycetes in different experimental groups; F is the relative abundance expression of Proteobacteria in different experimental groups. * indicates significant difference (p<0.05).

[0024] Figure 4 It is the determination result of the genus-level composition of intestinal flora of mice in different experimental groups (top ten). Among them, A is the clustering abundance diagram of the genus level of intestinal flora of mice in different experimental groups; B is the relative abundance expression of the genus Lachnospiraceae_NK4A136_ in different experimental groups; C is the relative abundance expression of the genus Clostridium in different experimental groups; D is the relative abundance expression of the genus Eubacterium in different experimental groups; E is the relative abundance expression of the genus Ruminococcus in different experimental groups; * indicates significant difference (p<0.05). Detailed Embodiments

[0025] Next, the technical solution of the present invention will be described in conjunction with embodiments. However, the present invention is not limited to the following embodiments.

[0026] In order to enable those skilled in the art to better understand and implement the technical solution of the present invention, the present invention will be further described below in conjunction with specific embodiments and drawings. However, the embodiments cited are not intended to limit the present invention.

[0027] In the following embodiments, the experimental methods and detection methods are all conventional methods unless otherwise specified; the reagents and materials can be purchased on the market unless otherwise specified.

[0028] Alpinia officinarum was purchased from Xuwen County, Guangdong.

[0029] Example 1

[0030] This example is for preparing a crude polysaccharide solution of Alpinia officinarum polysaccharide.

[0031] Use a Chinese herbal medicine grinder to fully pulverize Alpinia officinarum, pass through a 40-mesh sieve to obtain Alpinia officinarum powder, and place it in a cool and dry place for later use.

[0032] Weigh 300 g of Alpinia officinarum powder, add 95% ethanol according to the solid-liquid ratio of 1:10 (exemplarily, 1 g of Alpinia officinarum powder and 10 g of 95% ethanol), reflux and extract at 85 °C for 1 h, filter by suction, collect the filtrate, repeat the extraction method for the residue 2 times, combine the filtrates, concentrate under reduced pressure at 55 °C to 1 / 5 of the original volume, and store it at -20 °C for later use; dry the residue at 60 °C until the ethanol completely volatilizes, and store it at 4 °C for subsequent extraction of Alpinia officinarum polysaccharide. Accurately weigh 60 g of the above-mentioned Alpinia officinarum extraction residue, add deionized water according to the solid-liquid ratio of 1:20, perform high-temperature treatment at 105 °C for 90 minutes to fully gelatinize the starch therein to obtain suspension 1, naturally cool it at room temperature, adjust the pH of suspension 1 to 5.5, add α-amylase at 1% (w / w) of the sample mass, enzymatically hydrolyze at 60 °C for 120 minutes to obtain suspension 2, adjust the pH of suspension 2 to 5.0, add glucoamylase at 1% (w / w) of the sample mass, and at the same time add cellulase at 1% (w / w) of the sample mass, enzymatically hydrolyze at 55 °C for 16 h to fully hydrolyze the starch in the sample and at the same time accelerate the dissolution of Alpinia officinarum polysaccharide to obtain suspension 3, adjust the pH of suspension 3 to 7.0, perform high-temperature treatment at 105 °C for 2 h, filter by suction and collect the filtrate, concentrate under reduced pressure at 55 °C, then add a certain amount of absolute ethanol to the system so that the ethanol concentration in the system is 80% (v / v), slowly stir evenly and then let it stand at 4 °C for 12 h, centrifuge at 8000 g for 30 min, collect the precipitate, add deionized water to dissolve the precipitate and make the volume constant to 50 mL to obtain a crude polysaccharide solution of Alpinia officinarum polysaccharide.

[0033] Example 2

[0034] This example is for preparing the freeze-dried powder of crude polysaccharide from Alpinia officinarum Hance.

[0035] Weigh 300 g of Alpinia officinarum Hance powder, add 95% ethanol according to the solid-liquid ratio of 1:10 (exemplarily, 1 g of Alpinia officinarum Hance powder and 10 g of 95% ethanol), reflux and extract at 85 °C for 1 h, perform suction filtration, collect the filtrate, repeat the extraction method for the residue 2 times, combine the filtrates, concentrate under reduced pressure at 55 °C to 1 / 5 of the original volume, and store it at -20 °C for standby; dry the residue at 60 °C until the ethanol completely volatilizes, and store it at 4 °C for subsequent extraction of Alpinia officinarum Hance polysaccharide. Accurately weigh 60 g of the above-mentioned Alpinia officinarum Hance extraction residue, add deionized water according to the solid-liquid ratio of 1:20, perform high-temperature treatment at 105 °C for 90 minutes to fully gelatinize the starch therein, obtain suspension 1, naturally cool it at room temperature, adjust the pH of suspension 1 to 5.5, add α-amylase at 1% (w / w) of the sample mass, enzymatically hydrolyze at 60 °C for 120 minutes to obtain suspension 2, adjust the pH of suspension 2 to 5.0, add glucoamylase at 1% (w / w) of the sample mass, enzymatically hydrolyze at 55 °C for 16 h to fully hydrolyze the starch in the sample and accelerate the dissolution of Alpinia officinarum Hance polysaccharide, obtain suspension 3, adjust the pH value of suspension 3 to 7.0, perform high-temperature treatment at 105 °C for 2 h, perform suction filtration and collect the filtrate, concentrate under reduced pressure at 55 °C, then add a certain amount of absolute ethanol to make the ethanol concentration in the system 80% (v / v), slowly stir evenly and then stand at 4 °C for 12 h, centrifuge at 8000 g for 30 min, collect the precipitate, redissolve the precipitate with deionized water, concentrate under reduced pressure at 55 °C to remove the residual ethanol therein, and prepare the freeze-dried powder of crude polysaccharide from Alpinia officinarum Hance by freeze-drying.

[0036] Example 3

[0037] This example is for the purification of crude polysaccharide from Alpinia officinarum Hance.

[0038] The crude polysaccharide from Alpinia officinarum Hance obtained in Example 1 and Example 2 also contains proteins and small molecules. To further improve the polysaccharide purity, a protein removal treatment is required. In this example, enzymatic protein removal is used. Specifically, add papain at 1% of the sample content to the crude polysaccharide solution of Alpinia officinarum Hance for enzymatic hydrolysis, enzymatically hydrolyze at 37 °C for 4 h, then remove salts by dialysis method, add XAD-16 macroporous resin, keep at 37 °C, 120 rpm, perform constant-temperature static adsorption for 3 h to remove small molecule peptides and part of the pigments, then perform suction filtration and collect the filtrate, and concentrate under reduced pressure at 55 °C to obtain the polysaccharide from Alpinia officinarum Hance.

[0039] Example 4

[0040] This example is an animal experiment on the improvement effect of polysaccharide from Alpinia officinarum Hance on mice with high uric acid-induced intestinal flora imbalance.

[0041] 1. Establish the experimental model

[0042] Thirty male SPF - level Kunming mice (27 ± 2 g, 7 - week - old) were randomly divided into 5 groups (control group, model group, low - dose galangal polysaccharide group, medium - dose galangal polysaccharide group, high - dose galangal polysaccharide group), with 6 mice in each group. The intragastric administration doses of the low, medium, and high - dose groups in the galangal polysaccharide group were 75 mg / kg, 150 mg / kg, and 250 mg / kg respectively. In the morning, the galangal polysaccharide solution was intragastrically administered, and in the afternoon, 75 mg / kg adenine solution and 300 mg / kg potassium oxonate solution were intragastrically administered. In the model group, 0.1 mL / 10 g normal saline was intragastrically administered in the morning, and 75 mg / kg adenine solution and 300 mg / kg potassium oxonate solution were intragastrically administered in the afternoon. In the control group, 0.1 mL / 10 g normal saline was intragastrically administered both in the morning and afternoon. After the intragastric administration of each group of mice every day, the mice in each group were allowed to feed freely. The experimental groups (control group, model group, galangal polysaccharide group) were intragastrically administered continuously for 21 days. After the last intragastric administration, the mice were sacrificed, and the colon tissues and cecal contents were collected.

[0043] 2. Determination of the relative expression levels of Occludin and ZO - 1 in mouse colon tissues

[0044] Tight junction proteins are important indicators for maintaining the integrity of the intestinal barrier. Tight junction proteins (Occludin) and zonula occludens protein - 1 (ZO - 1) are common tight junction proteins and play a key role in maintaining intestinal barrier function and other physiological barriers.

[0045] Take 20 mg of colon tissue and add it to RIPA strong lysis buffer (purchased from Shanghai Beyotime Biotechnology Co., Ltd.) containing PMSF at a ratio of 1:100 and phosphatase inhibitor at a ratio of 1:50. After grinding, it was lysed at 4°C for 20 min, centrifuged at 4°C and 12,000 rpm for 20 min to collect the supernatant. Subsequently, a protein quantification kit (purchased from Shanghai Beyotime Biotechnology Co., Ltd.) was used to measure the concentration of each sample. After adjusting them to be consistent, 5×SDS loading buffer was added. Subsequently, the protein was denatured at 100°C for 10 min. SDS - PAGE electrophoresis was used to separate the proteins, and then the proteins were transferred to a nitrocellulose membrane. After blocking at room temperature for 1 h, it was incubated overnight at 4°C with primary antibodies GAPDH, Occludin, and ZO - 1 (antibody dilution ratio is 1:1000). Subsequently, it was incubated with the corresponding secondary antibody (dilution ratio 1:3000) at room temperature for 1 h and then soaked in the hypersensitive ELC working solution, and imaged using a chemiluminescence system to obtain a protein band diagram as shown in Figure 1 A in. The protein band diagram was analyzed for gray scale using ImageJ software, and the final data was presented as the ratio of the gray scale of the target protein to the gray scale of the internal reference GAPDH. The results of the determination of the relative expression levels of Occludin and ZO - 1 in mouse colon tissues are shown in Figure 1 B in.

[0046] Figure 1 The results of B in showed that compared with the control group, the expressions of tight junction proteins Occludin and ZO-1 in the colon tissues of the hyperuricemia exposure model group were significantly decreased, indicating that hyperuricemia caused damage to the intestinal physical barrier and disruption of integrity. After the action of galangal polysaccharide, the expressions of tight junction proteins were up-regulated. Under the action of the low-dose, medium-dose, and high-dose galangal polysaccharide groups, the expression of ZO-1 was up-regulated by 1.9, 1.4, and 1.5 times respectively, and the expression of Occludin was up-regulated by 2.3, 1.8, and 1.4 times respectively, improving intestinal integrity. The results showed that galangal polysaccharide could effectively repair the intestinal barrier damage induced by hyperuricemia and slow down the occurrence of intestinal flora dysbiosis, and the high-dose galangal polysaccharide group had the best effect.

[0047] 3. High-throughput sequencing of 16S rDNA in mouse cecal contents

[0048] After sacrificing the mice in the control group, model group, and galangal polysaccharide group (250 mg / kg), cecal contents were collected, and genomic DNA was extracted from the contents using a nucleic acid extraction kit. Qualified DNA samples were subjected to PCR amplification of the V4 region of 16S rDNA with universal primers 515F and 806R. The sequence of 515F is shown in SEQ ID NO:1, and the sequence of 806R is shown in SEQ ID NO:2.

[0049] After purification and quantification of the PCR products, libraries were constructed and merged into the Illumina NovaSeq sequencing platform for paired-end sequencing to obtain the original sequences. ASVs clustering was performed at a specific similarity, and the clustering results were used to annotate the species and analyze the abundance of the representative sequences by Qiime2. Further sequence data analysis was performed using Qiime2 and R package (v3.2.0). After the quality assessment of the flora samples, intestinal flora diversity analysis and analysis of the changes in the phylum and genus levels of the intestinal flora species composition were performed respectively. The diversity results are shown in Table 1 and Figure 2 as shown, and the results of the changes in the flora species composition are shown in Figure 3 and Figure 4 as shown.

[0050] Alpha diversity and Beta diversity are indicators for evaluating the intra-group and inter-group diversity changes of the intestinal flora. Among them, Alpha diversity is often shown by the Chao1, ACE, pielou_e, Shannon, and Simpson indices. As shown in Table 1, the Alpha diversity of the mice in each group changed little, and there were no significant differences in the Chao1 and ACE indices among the groups, indicating that hyperuricemia exposure had little effect on the overall richness and diversity within the flora species group, and it was a chronic intestinal flora dysbiosis model. After the intervention of galangal polysaccharide, all the indices were improved, suggesting that galangal polysaccharide improved the intra-group diversity of the flora by enriching the dominant flora.

[0051] Table 1 Determination results of Alpha diversity index of intestinal flora in mice of different experimental groups

[0052]

[0053] Note: Different lowercase letters indicate significant differences

[0054] It can be seen from Figure 2 that the flora structures of the control group and the model group deviated greatly, indicating that high uric acid exposure caused intestinal flora dysbiosis. After the action of galangal polysaccharide, it can regulate Beta diversity to improve the flora structure.

[0055] Figure 3 and Figure 4 respectively show the changes in the composition of intestinal flora at the phylum and genus levels. It can be seen from the A clustering abundance map in Figure 3 that high uric acid exposure disrupts the balance of intestinal flora, and the abundances of a large number of microorganisms change, while the above situation can be reversed after the intervention of galangal polysaccharide. In each group of mice, Firmicutes and Bacteroidetes accounted for the vast majority of the flora composition at the phylum level, and the ratio of Firmicutes to Bacteroidetes is an important indicator to measure the balance of intestinal flora.

[0056] From Figure 3 in B and Figure 3 in C, it can be seen that high uric acid exposure increased the abundance of Firmicutes and decreased the abundance of Bacteroidetes. From Figure 3 in D, it can be seen that the ratio of Firmicutes (F) / Bacteroidetes (B) increased, indicating the occurrence of intestinal flora dysbiosis in the body. Figure 3 in E and Figure 3 in F show that the relative abundances of Proteobacteria and Planctomycetes, which contain more potential pathogenic bacteria, were significantly up-regulated after high uric acid exposure. After the action of galangal polysaccharide, the F / B ratio and the compositional abundances of Proteobacteria and Planctomycetes can be down-regulated to a certain extent. When further analyzing the compositional abundances at the genus level, it can be seen from Figure 4As can be seen from A in [the relevant context], at the genus level of each group of mice, the genus Lachnospiraceae_NK4A136_ occupies the largest proportion, followed by Lactobacillus, Clostridium, Enterorhabdus, Anaerostipes, and Enterobacter, etc. Among the top 10 genera, high uric acid exposure upregulates the abundances of the genus Lachnospiraceae_NK4A136_ and Clostridium, and downregulates the abundances of Ruminococcus and Eubacterium. Lachnospiraceae_NK4A136_ has been proven to be a potential biomarker for nanoplastics exposure in food and has a strong correlation with hepatotoxicity. In addition, Lachnospiraceae_NK4A136_ plays an important role in D-galactose-induced intestinal microbiota disorder in mice, and the intestinal microbiota dysbiosis can be improved by downregulating its abundance. Clostridium is widely distributed in nature. The common pathogenic anaerobic spore-forming Clostridia mainly include Clostridium tetani, Clostridium perfringens, Clostridium botulinum, and Clostridium difficile, etc., which are closely related to diseases such as gas gangrene and pseudomembranous colitis. Ruminococcus plays an important role in the digestion of resistant starch, but is also related to intestinal diseases (ulcerative colitis, Crohn's disease, etc.), immune diseases (allergies, eczema, asthma, etc.), neurological diseases (autism, depression, etc.), and liver diseases (metabolic associated fatty liver disease). Eubacterium plays a key role in processes such as cholesterol conversion, oxalate catabolism, and insulin degradation. Therefore, its reduction or deficiency can lead to the occurrence of various diseases such as depression, obesity, diabetes, colorectal cancer, autism, and cardiovascular and cerebrovascular diseases. It can be seen from this result that high uric acid exposure can induce the upregulation of multiple potential pathogenic bacteria and cause the downregulation of beneficial bacteria, disrupting the original microbiota structure. After the action of galangal polysaccharide, it can downregulate the abundances of various potential harmful bacteria caused by high uric acid exposure, showing its great potential as a new prebiotic.

[0057] As described above, the basic principles, main features, and advantages of the present invention are preferably described. The above embodiments and the description are only for describing the preferred embodiments of the present invention. The present invention is not limited by the above embodiments. Without departing from the spirit and scope of the present invention, various changes and improvements made by those of ordinary skill in the art to the technical solutions of the present invention should fall within the protection scope determined by the present invention.

Claims

1. Use of galangal polysaccharide in the preparation of a drug for improving intestinal flora imbalance, characterized in that, The galangal polysaccharide is obtained by extracting from galangal; the intestinal flora dysbiosis is induced by hyperuricemia; the intestinal flora dysbiosis includes intestinal barrier damage and / or deviation of flora structure; the intestinal barrier damage includes down-regulation of the expression of tight junction protein Occludin and / or ZO-1 protein representing intestinal barrier integrity; the deviation of flora structure includes significant changes in Beta diversity representing the intra-group and inter-group diversity of the intestinal flora.

2. The application according to claim 1, characterized in that, The administration method of the galangal polysaccharide is intragastric administration.

3. The application according to claim 1, wherein The galangal polysaccharide repairs the intestinal barrier damage induced by hyperuricemia, and the administration concentration of the galangal polysaccharide is 75 mg / kg to 250 mg / kg.

4. The application according to claim 3, wherein The administration concentration of the galangal polysaccharide is 250 mg / kg.

5. The application according to claim 1, characterized in that, The galangal polysaccharide alleviates the deviation of flora structure induced by hyperuricemia, and the alleviation is achieved by regulating the Beta diversity of the intestinal flora.

6. The application according to claim 5, characterized in that, The regulation of the Beta diversity of the intestinal flora includes down-regulating Firmicutes and / or down-regulating Planctomycetes and / or down-regulating Proteobacteria and / or up-regulating Bacteroidetes at the phylum level of the intestinal flora composition.

7. The application according to claim 6, characterized in that The regulation of the Beta diversity of the intestinal flora includes down-regulating Clostridium and / or up-regulating Ruminococcus and / or up-regulating Eubacterium at the genus level of the intestinal flora composition.

Images